Esperas Pharma Inc., a Montréal, Québec, Canada-based special purpose company created to develop one compound to proof-of-concept, raised a vc funding of undisclosed amount.
Backers included TVM Life Science Ventures VII and the Fonds de solidarité FTQ.
Led by Caroline Fortier, CEO, and Mark Cipriano, CFO, Esperas Pharma aims to develop, to proof-of-concept, a compound originally discovered through one of Eli Lilly and Company’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer.
Esperas will be initiating the first human dose study in multiple types of cancers. Cohort expansions are planned in several different tumors, including triple negative breast cancer. Triple negative breast cancer (TNBC) refers to a tumor type that is negative for the receptors for progesterone and estrogen as well as being negative for Her2/Neu making this type of tumor particularly difficult to treat. In addition to TNBC, the company will explore the development of this anti-cancer agent in other solid tumor types that continue to be poorly served by currently approved treatments.